Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer

Dr Julia Rotow talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using concurrent osimertinib plus gefitinib for treating EGFR-mutated NSCLC.

The EGFR TKI osimertinib is active against the acquired gefitinib-resistant mutation EGFR T790M, as is gefitinib against the osimertinib-resistant EGFR C797S. Preclinical evidence suggests dual EGFR inhibition with gefitinib + osimertinib may delay emergence of acquired resistance.

Dr Rotow outlines the trial design and results, and how this regimen will impact clinical practice.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php